Superficial spreading melanoma stage III

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
4 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Checkpoint inhibitor (PD-1) 1 substance
Phase III: 1 Phase I (First in Human): 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

1 trial
  • Philogen S.p.A. Commercial
    BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
    2023-507119-36-00 4 countries 2022 n=170
    Recruiting

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; NIVOLUMAB
    2024-513062-19-00 1 country 2022 n=8
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Philogen S.p.A. Commercial 1 Phase III 1
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
New trials by year
2022
2
← All indication landscapes